<--- Back to Details
First PageDocument Content
Immunology / Anatomy / Vaccination / Cancer immunotherapy / Monoclonal antibodies / Biologic / Oncolytic virus / MedImmune / Vaccine / Medicine / Biology / Immune system
Date: 2012-02-03 08:49:45
Immunology
Anatomy
Vaccination
Cancer immunotherapy
Monoclonal antibodies
Biologic
Oncolytic virus
MedImmune
Vaccine
Medicine
Biology
Immune system

Microsoft PowerPoint - Doroshow.pptx

Add to Reading List

Source URL: deainfo.nci.nih.gov

Download Document from Source Website

File Size: 1.019,30 KB

Share Document on Facebook

Similar Documents

Commited to Biologic Innovation

DocID: 1tUBq - View Document

Special Authorization Criteria for Biologic Drugs For each disease category specified below, the biologic drugs listed will only be considered for reimbursement if the patient has failed an adequate trial or experienced

DocID: 1tOXv - View Document

ASX ANNOUNCEMENT 10 February 2014 Cynata Partners With Leading Biologic Product Manufacturer Cynata Therapeutics Ltd (ASX:CYP), announced today that it has signed a manufacturing agreement

DocID: 1tf2X - View Document

Stakeholder Meeting on PDUFA VI Reauthorization September 28, 2015, 1:30 PM – 3.05 PM FDA White Oak Campus, Silver Spring, MD Purpose To discuss the current status of the human drug and biologic review programs, review

DocID: 1t2jx - View Document

Council Report AVMA Council on Biologic and Therapeutic Agents’ report on cat and dog vaccines Donald J. Klingborg, DVM; David R. Hustead, DVM; Elizabeth A. Curry-Galvin, DVM; Nigel R. Gumley, DVM, DABVP; Steven C. Hen

DocID: 1s94L - View Document